Syringic acid pretreatment potentiates antioxidant mechanism and downregulates inflammatory signaling towards doxorubicin-related oxidoinflammatory hepatorenal damage in rats

ArticleAçık Erişim

Özet

Although doxorubicin (DOX) is a first-line antineoplastic drug, its clinical use is limited due to its widespread side effects. Hepatic and renal metabolic clearance causes DOX accumulation in these organ systems, ultimately leading to oxidative-inflammatory damage. This study investigated the potential impact of syringic acid (SA), a natural antioxidant phenolic compound, against in vivo DOX-evoked hepatorenal damage. SA was orally administered to rats at 100 mg/kg body weight for 10 consecutive days. On the 8th day of the study, DOX was administered at 20 mg/kg by single-dose intraperitoneal injection to prompt hepatorenal toxicity. Hepatorenal toxicity was assessed by measuring serum alanine transferase (ALT), aspartate transferase (AST), blood urea nitrogen (BUN), and creatinine (Cre). Histopathological evaluation of kidney and liver tissues was also performed to observe DOX-related damage. The concentrations of malondialdehyde (MDA) and glutathione (GSH), along with the activities of catalase (CAT) and superoxide dismutase (SOD), were measured in the hepatorenal tissues, in addition to the concentration of 8-OHdG in serum, to determine the protective effect of SA against oxidative stress. Tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) levels were investigated with molecular and immunohistochemical analysis in hepatorenal tissues, evaluating the inflammation. SA treatment prevented DOX-aberrant elevation of hepatorenal biomarkers in serum, besides histopathological alterations in rats’ liver and kidney. Additionally, SA markedly counteracted DOX-provoked oxidative damage as evidenced by outstanding reduction in lipid peroxidation and 8-OHdG, conjointly promoted GSH contents, and amelioration of activities of SOD and CAT. Similarly, SA-treated rats exhibited attenuation of hepatorenal inflammation via diminished TNF-α and IL-6 levels. SA exerted a hepatorenal protective effect in rats by exhibiting antioxidant and anti-inflammatory activities. © The Author(s) 2026.

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/ebyu/10234Resmi atıflarda kullanılan kalıcı adres
DOI
https://doi.org/10.1038/s41598-026-59075-9Yayıncı resmi DOI adresi
Tam Kayıt
AlanDeğerDil
dc.contributor.authorKaradogan, Muhammed Talha
dc.contributor.authorYeni, Yesim
dc.contributor.authorYeter, Bahtinur
dc.contributor.authorGungor, Ali
dc.contributor.authorAltuner, Durdu
dc.contributor.authorAzade, Faraz
dc.contributor.authorGursul, Cebrail
dc.contributor.authorSuleyman, Halis
dc.date.accessioned2026-10-18T20:25:29.197872191Z
dc.date.available2026-10-18T20:25:29.197872191Z
dc.date.issued2026
dc.description.abstractAlthough doxorubicin (DOX) is a first-line antineoplastic drug, its clinical use is limited due to its widespread side effects. Hepatic and renal metabolic clearance causes DOX accumulation in these organ systems, ultimately leading to oxidative-inflammatory damage. This study investigated the potential impact of syringic acid (SA), a natural antioxidant phenolic compound, against in vivo DOX-evoked hepatorenal damage. SA was orally administered to rats at 100 mg/kg body weight for 10 consecutive days. On the 8th day of the study, DOX was administered at 20 mg/kg by single-dose intraperitoneal injection to prompt hepatorenal toxicity. Hepatorenal toxicity was assessed by measuring serum alanine transferase (ALT), aspartate transferase (AST), blood urea nitrogen (BUN), and creatinine (Cre). Histopathological evaluation of kidney and liver tissues was also performed to observe DOX-related damage. The concentrations of malondialdehyde (MDA) and glutathione (GSH), along with the activities of catalase (CAT) and superoxide dismutase (SOD), were measured in the hepatorenal tissues, in addition to the concentration of 8-OHdG in serum, to determine the protective effect of SA against oxidative stress. Tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) levels were investigated with molecular and immunohistochemical analysis in hepatorenal tissues, evaluating the inflammation. SA treatment prevented DOX-aberrant elevation of hepatorenal biomarkers in serum, besides histopathological alterations in rats’ liver and kidney. Additionally, SA markedly counteracted DOX-provoked oxidative damage as evidenced by outstanding reduction in lipid peroxidation and 8-OHdG, conjointly promoted GSH contents, and amelioration of activities of SOD and CAT. Similarly, SA-treated rats exhibited attenuation of hepatorenal inflammation via diminished TNF-α and IL-6 levels. SA exerted a hepatorenal protective effect in rats by exhibiting antioxidant and anti-inflammatory activities. © The Author(s) 2026.
dc.identifier.doi10.1038/s41598-026-59075-9
dc.identifier.issn2045-2322
dc.identifier.issue1
dc.identifier.pmcidPMC13572440
dc.identifier.pmid42331909
dc.identifier.scopus2-s2.0-105050341513
dc.identifier.startpage28576
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/10234
dc.identifier.volume16
dc.identifier.wosWOS:001874781200007
dc.language.isoen
dc.publisherNature Research
dc.relation.ispartofScientific Reports
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAntioxidant
dc.subjectDoxorubicin
dc.subjectHepatorenal toxicity
dc.subjectInflammation
dc.subjectOxidative stress
dc.subjectRat
dc.subjectSyringic acid
dc.subjectAnimals
dc.subjectAntioxidants
dc.subjectCatalase
dc.subjectChemical and Drug Induced Liver Injury
dc.subjectGallic Acid
dc.subjectGlutathione
dc.subjectInterleukin-6
dc.subjectKidney
dc.subjectLiver
dc.subjectMale
dc.subjectMalondialdehyde
dc.subjectRats
dc.subjectSignal Transduction
dc.subjectSuperoxide Dismutase
dc.subjectTumor Necrosis Factor-alpha
dc.subjectinterleukin 6
dc.subjectmalonaldehyde
dc.subjecttumor necrosis factor
dc.subjectanimal
dc.subjectdrug effect
dc.subjectdrug therapy
dc.subjectmetabolism
dc.subjectpathology
dc.titleSyringic acid pretreatment potentiates antioxidant mechanism and downregulates inflammatory signaling towards doxorubicin-related oxidoinflammatory hepatorenal damage in rats
dc.typeArticle
dspace.entity.typePublication
rdl.citation.scopus0
rdl.citation.wos0
rdl.departmentDepartment of Child Health and Diseases, Faculty of Medicine, Erzincan Binali Yildirim University, Erzincan, Turkey. | Department of Pharmacology, Faculty of Medicine, Erzincan Binali Yildirim University, Erzincan, Turkey. | Department of Physiology, Faculty of Medicine, Erzincan Binali Yildirim University, Erzincan, Turkey. | Department of Pharmacology, Faculty of Medicine, Erzincan Binali Yildirim University, Erzincan, Turkey. halis.suleyman@gmail.com.
rdl.oa.statusgold
rdl.source.indexSCOPUS
rdl.source.indexWOS
rdl.source.indexPUBMED
rdl.wos.indexScience Citation Index Expanded (SCI-EXPANDED)